ArticleFrontiers in microbiology2025
Impact of the COVID-19 pandemic on vancomycin-resistant
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Shift of antibiotic resistance after the COVID-19 pandemic: results from the INVIFAR Network.JAC-antimicrobial resistance · 2026Article
- Temporal Trends and Mortality of Vancomycin-ResistantPathogens (Basel, Switzerland) · 2026Observational
- Dynamic screening strategies for the control of a prolonged vancomycin-resistant enterococci outbreak: A decade-long study in a Japanese tertiary hospital.Epidemiology and infection · 2026Article
- Surgical Site Infections and Antimicrobial Resistance: Six Years of Data from a Western Romanian Hospital.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antimicrobial resistance is a critical and growing global health concern. While drug-resistant Gram-negative bacilli pose a significant threat, multidrug-resistant Gram-positive bacteria-such as methicillin-resistant Aim: This study provides an epidemiological analysis of resistant Gram-positive bacteria, focusing on VRE, at a tertiary university hospital in Western Greece from 2018 to 2023. Results: A total of 276 blood cultures with vancomycin-resistant Conclusion: The number of VRE increased over the study period. Linezolid and tigecycline remained largely effective, but emerging resistance patterns-particularly to daptomycin-underscore the urgent need for strengthened antimicrobial stewardship and the development of novel therapeutic options to address rising resistance among Gram-positive pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.